Worldwide Clinical Trials

JULY 8, 2024

Genetic Factors : Certain genetic mutations, such as those in DNA repair genes, can affect how cells respond to radiation. Individuals with familial cancer syndrome may have inherited mutations that predispose them to cancer development, affecting genes involved in DNA repair and cell cycle regulation.

Hormones 130

Hormones Regulation Clinical Trials Clinical Trials 130

pharmaphorum

APRIL 7, 2021

The collaboration will focus on combining Artios’ DNA damage response (DDR) drug candidates with Novartis’ radioligand therapies, which consist of tumour-targeting molecules carrying radioactive isotopes that can deliver a cell-killing dose of radiation to malignant cells. The drug made $445 million in sales last year.

DNA 52

DNA Licensing Licensing Gene Therapy 52

XTalks

JANUARY 26, 2024

This technology, which allows for precise editing of DNA at specific locations, has been a major focus in the field due to its potential to directly target and modify cancer-causing genes. Overcoming drug resistance: A major challenge in cancer treatment is the development of resistance to chemotherapy drugs.

Research 118

Research Gene Editing Gene Genetics 118

XTalks

JANUARY 19, 2024

Over the last year, there have been new acquisitions, launches and deals for novel radiotherapeutics and newly created peptide-radioisotope drug conjugates. When alpha-emitting radionuclides are delivered to cancer cells, the emitted alpha particles cause substantial damage to the DNA of the cells, leading to cell death.

DNA 66

DNA Radiology FDA Approval Development 66

XTalks

NOVEMBER 7, 2022

Liquid biopsy tests in oncology involve isolating entities such as circulating tumor cells (CTC), circulating tumor DNA (ctDNA) and tumor-derived exosomes. The cfDNA that originates from tumors is called circulating tumor DNA (ctDNA). These tumor-derived entities are used to derive genomic and proteomic data.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

XTalks

MARCH 10, 2021

Along with COVID-19 vaccine authorizations, the US Food and Drug Administration (FDA) remains committed to increasing access to COVID-19 tests and supporting their development, having authorized three new tests recently for emergency use. The products encompass molecular, antigen and T cell-based testing approaches.

Protein 98

Protein RNA Antibody Production 98

The Pharma Data

APRIL 20, 2022

Food and Drug Administration is warning the public of the risk of false results, inappropriate use and inappropriate interpretation of results with non-invasive prenatal screening (NIPS) tests, also called cell-free DNA tests or non-invasive prenatal tests (NIPT). director of the FDA’s Center for Devices and Radiological Health.

Genetics 52

Genetics Cosmetics Radiology Production 52